Phase I single-agent, dose-escalating, multiple-dose trial of SF 1126 in patients with multiple myeloma and B-cell malignancies, including chronic lymphocytic leukaemia, indolent non-Hodgkin's lymphoma, and mantle cell lymphoma (MCL)

Trial Profile

Phase I single-agent, dose-escalating, multiple-dose trial of SF 1126 in patients with multiple myeloma and B-cell malignancies, including chronic lymphocytic leukaemia, indolent non-Hodgkin's lymphoma, and mantle cell lymphoma (MCL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2010

At a glance

  • Drugs SF 1126 (Primary)
  • Indications Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Semafore Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2010 Results from patients with B-cell malignancies will be presented at ASH-2010, according to a Semafore Pharmaceuticals media release.
    • 22 Jun 2010 Preliminary results indicating activity in patients with CLL presented at the Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference, according to a Semafore Pharmaceuticals media release.
    • 21 Apr 2010 The first patient with a B-cell malignancy was dosed in April 2010, as reported by a Semafore Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top